This pace is expected to maintain the €200 million annual volume that the industry has been delivering for the past few years.
According to the Medicines Agency, around 92% of supplies were imported and only 7.5% locally produced.
The market is still not growing in physical terms, but exclusively in money.
Thus, in the first three months of 2025, 19.2 million packs were imported (down 5%) and another 3.75 million packs of medicines were locally produced. The Agency for Medicines explains this difference by the increase in prices for a number of new generation drugs.
About 12.6% of all medicines in Moldova were imported from Germany and Romania (10.3% each), Slovenia (9%), Turkey (8.4%), Hungary (5.7%).
Among the most demanded foreign medicines were dapagliflozin (turnover of 1.6 million euros), ibuprofen (1.3 million euros), rosuvastatin (1.2 million euros), soludexin (1.1 million euros), pankeratin (0.9 million euros). Among locally produced medicines, tadalafil (EUR 0.5 million), xylometazoline (EUR 0.4 million), famotidine (EUR 0.35 million) and heparin (EUR 0.2 million) led the demand.
In the first quarter of 2025, the top 10 largest foreign suppliers are as follows: KRKA (EUR 5 million), Berlin-Chemie (EUR 4 million), Gedeon Richter (EUR 2.6 million), GlaxoSmithKline (EUR 2 million), Nobel (EUR 2 million), World Medicine (EUR 2 million), AstraZeneca (EUR 1.9 million), Abbott (EUR 1.7 million), Sanofi (EUR 1.6 million), Bayer (EUR 1.6 million).
The list of the largest local manufacturers is still headed by Balkan Pharmaceuticals with sales of €3.3 million. In second place is Flumed-Farm with EUR 0.7 million, in third place is Farmaprim with EUR 0.67 million.
